Disease evolution in multiple sclerosis

Multiple sclerosis is a long-term disease that evolves over a period of 30 to 40 years with progressive accumulation of unremitting disability. When developing treatments for multiple sclerosis, it is important to be able to measure accurately the impact of treatments on disability progression. An a...

詳細記述

書誌詳細
第一著者: Ebers, G
フォーマット: Conference item
出版事項: 2006
_version_ 1826286004057669632
author Ebers, G
author_facet Ebers, G
author_sort Ebers, G
collection OXFORD
description Multiple sclerosis is a long-term disease that evolves over a period of 30 to 40 years with progressive accumulation of unremitting disability. When developing treatments for multiple sclerosis, it is important to be able to measure accurately the impact of treatments on disability progression. An analysis of 31 previous clinical trials revealed that small changes in EDSS scores measured across two or three years may be insufficiently sensitive to detect sustained changes in disability reliably. Information from large longitudinal natural history databases indicates that long-term outcome is largely independent of previous relapse history, although the occurrence of relapses complicates the short-term quantification of unremitting disability. Treatment effects on relapses may thus not predict long-term effects on disability, although currently available data are insufficient to settle this issue. Natural history studies show that the principal determinant of long-term outcome is conversion to a progressive disease course, which may be related to neurodegeneration of specific neuronal pathways, for example the corticospinal tract. For this reason, it is important to develop tools to identify disease conversion that could be used in future clinical trials. © 2006 Steinkopff-Verlag.
first_indexed 2024-03-07T01:37:20Z
format Conference item
id oxford-uuid:95aaab8b-5e98-4c01-b5fd-f71ec4aaeb11
institution University of Oxford
last_indexed 2024-03-07T01:37:20Z
publishDate 2006
record_format dspace
spelling oxford-uuid:95aaab8b-5e98-4c01-b5fd-f71ec4aaeb112022-03-26T23:47:33ZDisease evolution in multiple sclerosisConference itemhttp://purl.org/coar/resource_type/c_5794uuid:95aaab8b-5e98-4c01-b5fd-f71ec4aaeb11Symplectic Elements at Oxford2006Ebers, GMultiple sclerosis is a long-term disease that evolves over a period of 30 to 40 years with progressive accumulation of unremitting disability. When developing treatments for multiple sclerosis, it is important to be able to measure accurately the impact of treatments on disability progression. An analysis of 31 previous clinical trials revealed that small changes in EDSS scores measured across two or three years may be insufficiently sensitive to detect sustained changes in disability reliably. Information from large longitudinal natural history databases indicates that long-term outcome is largely independent of previous relapse history, although the occurrence of relapses complicates the short-term quantification of unremitting disability. Treatment effects on relapses may thus not predict long-term effects on disability, although currently available data are insufficient to settle this issue. Natural history studies show that the principal determinant of long-term outcome is conversion to a progressive disease course, which may be related to neurodegeneration of specific neuronal pathways, for example the corticospinal tract. For this reason, it is important to develop tools to identify disease conversion that could be used in future clinical trials. © 2006 Steinkopff-Verlag.
spellingShingle Ebers, G
Disease evolution in multiple sclerosis
title Disease evolution in multiple sclerosis
title_full Disease evolution in multiple sclerosis
title_fullStr Disease evolution in multiple sclerosis
title_full_unstemmed Disease evolution in multiple sclerosis
title_short Disease evolution in multiple sclerosis
title_sort disease evolution in multiple sclerosis
work_keys_str_mv AT ebersg diseaseevolutioninmultiplesclerosis